(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Astronauts on the ISS watched NASA's historic Artemis 2 launch from space - 2In a scientific first, biologists recorded a wild wolf potentially using tools
- 3Doctor's orders? ‘Belly laugh at least two to five days a week'
- 4Slovakia rejects EU call to scrap higher fuel prices for foreign cars
- 5Gaza receiving over 70,000 cubic meters of water per day, COGAT claims
- Germany's Deutsche Welle broadcaster declared 'undesirable' in Russia
- Nearly 16,000 New York City nurses prepare to strike as contract talks stall
- This Week In Space podcast: Episode 203 — China Rising
- Rick Steves' Newest Guidebook Is A Fresh Perspective On Italy Spilling The Country's Secrets
- Four Dead in Last Month From Animal Attacks in Nepal
- German politician urges more face-to-face interaction in digital age
- Launch pad damaged as Russian rocket blasts off for space station, agency says
- What is the Significant Tech Expertise to Master Today?
- Iran plans new restrictions in overhaul of Strait of Hormuz rules
